

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 July 2025 (10.07.2025)



(10) International Publication Number
WO 2025/147228 A1

- (51) **International Patent Classification:**
A61K 31/07 (2006.01) *A61P 27/02* (2006.01)
A61K 31/22 (2006.01)
- (21) **International Application Number:**
PCT/US2024/010064
- (22) **International Filing Date:**
02 January 2024 (02.01.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (71) **Applicant:** **ALKEUS PHARMACEUTICALS, INC.**
[US/US]; 44 Brattle St, Fl 2, Cambridge, Massachusetts
02138 (US).
- (72) **Inventor:** **SAAD, Leonide C.**; 44 Brattle St, Fl 2, Cam-
bridge, Massachusetts 02138 (US).
- (74) **Agent:** **GODDARD, Christine A.** et al.; Fish & Richard-
son, P.O. Box 1022, Minneapolis, Minnesota 55440-1022
(US).

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— with international search report (Art. 21(3))

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) **Title:** TREATMENT FOR ASYMPTOMATIC STARGARDT DISEASE PATIENTS WITH GILDEURETINOL ACETATE




Fig. 1

(57) **Abstract:** Disclosed is a method of delaying the onset of Stargardt disease symptoms in an asymptomatic Stargardt disease patient. Also disclosed is a method of delaying the onset of vision loss in an asymptomatic Stargardt disease patient. Also disclosed is a method of treating a Stargardt disease patient to delay the onset of vision loss in the Stargardt disease patient, wherein treatment is initiated prior to the patient experiencing vision loss resulting from the Stargardt disease. The methods comprise administering to the patient an effective amount of gildeuretinol acetate.

WO 2025/147228 A1